欧洲卒中预防研究。2。潘生丁与阿司匹林的二级预防中风。

文章的细节

引用

复制到剪贴板

Diener HC,达L,福布斯C, Sivenius J,手中P, Lowenthal

欧洲卒中预防研究。2。潘生丁与阿司匹林的二级预防中风。

J神经科学。1996年11月,143 (2):1-13。

PubMed ID

8981292 (在PubMed

]

文摘

在1988年,我们进行了一项随机,安慰剂对照,双盲试验的安全性和有效性研究低剂量的阿司匹林(ASA), modified-release双嘧达莫,和两个代理相结合的二级预防缺血性中风。患者在中风或短暂性脑缺血发作(TIA)随机独自ASA治疗(每天50毫克),modified-release双嘧达莫(400毫克每天),联合制定的两个代理,或者安慰剂。主要终点是中风,一起死亡,中风或死亡。TIA和其他血管事件是次要的端点。病人在治疗随访两年。数据从6602例进行分析。因子分析显示出高度显著的影响对ASA和双嘧达莫在减少中风的危险(p < = 0.001)和中风或死亡(p < 0.01)。在成对比较,中风的风险相比安慰剂与ASA仅降低了18% (p = 0.013);仅16%,双嘧达莫(p = 0.039);与联合治疗和37% (p < 0.001)。 Risk of stroke or death was reduced by 13% with ASA alone (p = 0.016); 15% with dipyridamole alone (p = 0.015); and 24% with the combination (p < 0.001). The treatment had no statistically significant effect on the death rate alone. Factorial analysis also demonstrated a highly significant effect of ASA (p < 0.001) and dipyridamole (p < 0.01) for preventing TIA. The risk reduction for the combination was 36% (p < 0.001) in comparison with placebo. Headache was the most common adverse event, occurring more frequently in dipyridamole-treated patients. All-site bleeding and gastrointestinal bleeding were significantly more common in patients who received ASA in comparison to placebo or dipyridamole. We conclude that (1) ASA 25 mg twice daily and dipyridamole, in a modified-release form, at a dose of 200 mg twice daily have each been shown to be equally effective for the secondary prevention of ischemic stroke and TIA; (2) when co-prescribed the protective effects are additive, the combination being significantly more effective than either agent prescribed singly; (3) low-dose ASA does not eliminate the propensity for induced bleeding.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

双嘧达莫